Topic Editors

COMET-NANO Group, Department of Biology and Geology, Physics and Inorganic Chemistry, ESCET, Universidad Rey Juan Carlos, Calle Tulipán s/n, E-28933 Móstoles (Madrid), Spain
COMET-NANO Group, Department of Biology and Geology, Physics and Inorganic Chemistry, ESCET, Universidad Rey Juan Carlos, Calle Tulipán s/n, E-28933 Móstoles, Madrid, Spain

Nanomaterials and Diseases

Abstract submission deadline
13 August 2024
Manuscript submission deadline
13 October 2024
Viewed by
6380

Topic Information

Dear Colleagues,

As a very suitable technology for the diagnosis and treatment of various diseases, nanoparticles have emerged as tools in the field of medicine. The rapid development of nanomaterials has led to new methods for clinical diagnosis and provided a scientific basis for disease prevention and treatment. This Special Issue aims to highlight the current state of the art in the use of different nanomaterials in diseases, focusing on the future prospects of nanomaterials for improving current therapies in a preclinical context.

Dr. Diana Díaz-García
Prof. Dr. Santiago Gómez-Ruiz
Topic Editors

Keywords

  • targeted therapy
  • biocompatibility
  • nanomaterial
  • anticancer
  • cytotoxicity
  • diseases

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
4.5 8.0 2009 17.9 Days CHF 2900 Submit
Diseases
diseases
2.9 0.8 2013 18.8 Days CHF 1800 Submit
Nanomaterials
nanomaterials
4.4 8.5 2010 13.6 Days CHF 2900 Submit
Pharmaceuticals
pharmaceuticals
4.3 6.1 2004 14.6 Days CHF 2900 Submit
Materials
materials
3.1 5.8 2008 13.9 Days CHF 2600 Submit

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
21 pages, 5130 KiB  
Review
Trends in Nanoparticles for Leishmania Treatment: A Bibliometric and Network Analysis
by Gabriel Mazón-Ortiz, Galo Cerda-Mejía, Eberto Gutiérrez Morales, Karel Diéguez-Santana, Juan M. Ruso and Humberto González-Díaz
Diseases 2023, 11(4), 153; https://0-doi-org.brum.beds.ac.uk/10.3390/diseases11040153 - 28 Oct 2023
Viewed by 2063
Abstract
Leishmaniasis is a neglected tropical illness with a wide variety of clinical signs ranging from visceral to cutaneous symptoms, resulting in millions of new cases and thousands of fatalities reported annually. This article provides a bibliometric analysis of the main authors’ contributions, institutions, [...] Read more.
Leishmaniasis is a neglected tropical illness with a wide variety of clinical signs ranging from visceral to cutaneous symptoms, resulting in millions of new cases and thousands of fatalities reported annually. This article provides a bibliometric analysis of the main authors’ contributions, institutions, and nations in terms of productivity, citations, and bibliographic linkages to the application of nanoparticles (NPs) for the treatment of leishmania. The study is based on a sample of 524 Scopus documents from 1991 to 2022. Utilising the Bibliometrix R-Tool version 4.0 and VOSviewer software, version 1.6.17 the analysis was developed. We identified crucial subjects associated with the application of NPs in the field of antileishmanial development (NPs and drug formulation for leishmaniasis treatment, animal models, and experiments). We selected research topics that were out of date and oversaturated. Simultaneously, we proposed developing subjects based on multiple analyses of the corpus of published scientific literature (title, abstract, and keywords). Finally, the technique used contributed to the development of a broader and more specific “big picture” of nanomedicine research in antileishmanial studies for future projects. Full article
(This article belongs to the Topic Nanomaterials and Diseases)
Show Figures

Figure 1

14 pages, 4029 KiB  
Article
Activity of Bacteriophage D29 Loaded on Nanoliposomes against Macrophages Infected with Mycobacterium tuberculosis
by Ana P. B. Silva, Cesar Augusto Roque-Borda, Christian S. Carnero Canales, Laura Maria Duran Gleriani Primo, Isabel C. Silva, Camila M. Ribeiro, Marlus Chorilli, Patrícia Bento da Silva, Joás L. Silva and Fernando Rogério Pavan
Diseases 2023, 11(4), 150; https://0-doi-org.brum.beds.ac.uk/10.3390/diseases11040150 - 26 Oct 2023
Cited by 4 | Viewed by 1869
Abstract
The search for new antimicrobial agents is a continuous struggle, mainly because more and more cases of resistant strains are being reported. Mycobacterium tuberculosis (MTB) is the main microorganism responsible for millions of deaths worldwide. The development of new antimicrobial agents is generally [...] Read more.
The search for new antimicrobial agents is a continuous struggle, mainly because more and more cases of resistant strains are being reported. Mycobacterium tuberculosis (MTB) is the main microorganism responsible for millions of deaths worldwide. The development of new antimicrobial agents is generally aimed at finding strong interactions with one or more bacterial receptors. It has been proven that bacteriophages have the ability to adhere to specific and selective regions. However, their transport and administration must be carefully evaluated as an excess could prevent a positive response and the bacteriophages may be eliminated during their journey. With this in mind, the mycobacteriophage D29 was encapsulated in nanoliposomes, which made it possible to determine its antimicrobial activity during transport and its stability in the treatment of active and latent Mycobacterium tuberculosis. The antimicrobial activity, the cytotoxicity in macrophages and fibroblasts, as well as their infection and time–kill were evaluated. Phage nanoencapsulation showed efficient cell internalization to induce MTB clearance with values greater than 90%. Therefore, it was shown that nanotechnology is capable of assisting in the activity of degradation-sensitive compounds to achieve better therapy and evade the immune response against phages during treatment. Full article
(This article belongs to the Topic Nanomaterials and Diseases)
Show Figures

Graphical abstract

14 pages, 1750 KiB  
Article
The Impact of MiR-33a-5p Inhibition in Pro-Inflammatory Endothelial Cells
by Kun Huang, Mark Pitman, Olanrewaju Oladosu, Jing Echesabal-Chen, Lucia Vojtech, Ikechukwu Esobi, Jessica Larsen, Hanjoong Jo and Alexis Stamatikos
Diseases 2023, 11(3), 88; https://0-doi-org.brum.beds.ac.uk/10.3390/diseases11030088 - 24 Jun 2023
Cited by 1 | Viewed by 1737
Abstract
Evidence suggests cholesterol accumulation in pro-inflammatory endothelial cells (EC) contributes to triggering atherogenesis and driving atherosclerosis progression. Therefore, inhibiting miR-33a-5p within inflamed endothelium may prevent and treat atherosclerosis by enhancing apoAI-mediated cholesterol efflux by upregulating ABCA1. However, it is not entirely elucidated whether [...] Read more.
Evidence suggests cholesterol accumulation in pro-inflammatory endothelial cells (EC) contributes to triggering atherogenesis and driving atherosclerosis progression. Therefore, inhibiting miR-33a-5p within inflamed endothelium may prevent and treat atherosclerosis by enhancing apoAI-mediated cholesterol efflux by upregulating ABCA1. However, it is not entirely elucidated whether inhibition of miR-33a-5p in pro-inflammatory EC is capable of increasing ABCA1-dependent cholesterol efflux. In our study, we initially transfected LPS-challenged, immortalized mouse aortic EC (iMAEC) with either pAntimiR33a5p plasmid DNA or the control plasmid, pScr. We detected significant increases in both ABCA1 protein expression and apoAI-mediated cholesterol efflux in iMAEC transfected with pAntimiR33a5p when compared to iMAEC transfected with pScr. We subsequently used polymersomes targeting inflamed endothelium to deliver either pAntimiR33a5p or pScr to cultured iMAEC and showed that the polymersomes were selective in targeting pro-inflammatory iMAEC. Moreover, when we exposed LPS-challenged iMAEC to these polymersomes, we observed a significant decrease in miR-33a-5p expression in iMAEC incubated with polymersomes containing pAntimR33a5p versus control iMAEC. We also detected non-significant increases in both ABCA1 protein and apoAI-mediated cholesterol in iMAEC exposed to polymersomes containing pAntimR33a5p when compared to control iMAEC. Based on our results, inhibiting miR-33a-5p in pro-inflammatory EC exhibits atheroprotective effects, and so precisely delivering anti-miR-33a-5p to these cells is a promising anti-atherogenic strategy. Full article
(This article belongs to the Topic Nanomaterials and Diseases)
Show Figures

Figure 1

Back to TopTop